20.500.12556/RUL-135595 AKR1B1 and AKR1B10 as prognostic biomarkers of endometrioid endometrial carcinomas The roles of aldo-keto reductase family 1 member B1 (AKR1B1) and B10 (AKR1B10) in the pathogenesis of many cancers have been widely reported but only briefly studied in endometrial cancer. To clarify the potential of AKR1B1 and AKR1B10 as tissue biomarkers of endometrial cancer, we evaluated the immunohistochemical levels of AKR1B1 and AKR1B10 in tissue paraffin sections from 101 well-characterized patients with endometrioid endometrial cancer and 12 patients with serous endometrial cancer and compared them with the clinicopathological data. Significantly higher immunohistochemical levels of AKR1B1 and AKR1B10 were found in adjacent non-neoplastic endometrial tissue compared to endometrioid endometrial cancer. A trend for better survival was observed in patients with higher immunohistochemical AKR1B1 and AKR1B10 levels. However, no statistically significant differences in overall survival or disease-free survival were observed when AKR1B1 or AKR1B10 were examined individually in endometrioid endometrial cancer. However, analysis of AKR1B1 and AKR1B10 together revealed significantly better overall and disease-free survival in patients with both AKR1B1 and AKR1B10 staining above the median values compared to all other patients. Multivariant Cox analysis identified strong AKR1B1 and AKR1B10 staining as a statistically important survival prediction factor. Conversely, no significant differences were found in serous endometrial cancer. Our results suggest that AKR1B1 and AKR1B10 play protective roles in endometrioid endometrial cancer and show potential as prognostic biomarkers. endometrial carcinoma survival immunohistochemistry prognosis biomarker aldo-keto reductase family 1 member B1 (AKR1B1) aldo-keto reductase family 1 member B10 (AKR1B10) karcinom endometrija preživetje imunohistokemija true false true Angleški jezik Slovenski jezik Članek v reviji 2022-03-21 15:17:42 2022-03-21 15:17:44 2022-09-14 04:14:10 0000-00-00 00:00:00 2021 0 0 14 str. iss. 14, art. 3398 Vol. 13 Jul. 2021 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616-006 2072-6694 10.3390/cancers13143398 69972739 RAZ_Hojnik_Marko_2021.pdf RAZ_Hojnik_Marko_2021.pdf 1 DF1B0E9E3E55F3BC90616F471BFC7F53 d55eabf9a095c8628aba628d2263c561f67b709d09073a61a5f25eded195affa dd61badc-a921-11ec-8aca-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=154758 https://www.mdpi.com/2072-6694/13/14/3398 1 ada9c83c-a921-11ec-8aca-00155dcfd717 https://repozitorij.uni-lj.si/Dokument.php?lang=slv&id=154757 Medicinska fakulteta 0 0 0